Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab dose comparison versus placebo in systemic sclerosis
ChiCTR2300076972Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rituximab in systemic sclerosis (SSc) (3 arms), sponsored by Huashan Hospital. Primary endpoints: Modified Rodnan skin score, General impression of the patient's general health and 2 more. Started Dec 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ChiCTR2300076972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076972.